McCarthy, Eoghan M <br/><br/>
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.  [electronic resource] 

 -  Rheumatology (Oxford, England)  06 2017 
 - 1041-1043 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1462-0332 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/kex044  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>England<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Practice Guidelines as Topic<br/>Rituximab--therapeutic use<br/>Wales